What ISO 17034, CAP MOL checklist and CLIA 493.1253 require, accept, or are silent on for third-party reference material in LoD validation

1. Summary

For a laboratory-developed test, both CLIA and CAP's All Common checklist require the laboratory itself to establish analytical sensitivity (lower detection limit) before reporting patient results [1][7]. In the text of both that was read, the analytical-sensitivity requirement names no material type, no third-party source and no traceability condition [1][7]. The AMP/CAP 2017 NGS oncology-panel guideline is the only document read that recommends reference materials by name, in "should" language [4]. The current CAP MOL checklist and the ISO 17034 body text were not readable without crossing a paywall, and neither was the full text of the 2023 AMP/CAP cfDNA guideline [5][8][11].

2. What Changed

_Baseline (v1). No prior version; this establishes the starting point for future diffs._

3. Details

CLIA (42 CFR Part 493) — requires LoD; silent on the material

• 42 CFR 493.1253(b)(2): a laboratory that "introduces a test system not subject to FDA (US Food and Drug Administration) clearance or approval (including methods developed in-house …)" must, "before reporting patient test results, establish … (iii) Analytical sensitivity." The section names no material type and says nothing about traceability [1] [single-source].
• The only traceability language located in the adjacent sections concerns calibration, not LoD: calibration materials must be "appropriate for the test system and, if possible, traceable to a reference method or reference material of known value" (493.1255(a)(2)(i)) [2] [single-source].
• 493.1256(b): the laboratory "must establish the number, type, and frequency of testing control materials" — no source or traceability condition in the text retrieved [3] [single-source].

CAP checklist — requires LoD; accepts reference materials as one option

• COM.40400 (All Common Checklist, 2017-08-21 release, public CAP excerpt): "For modified FDA-cleared/approved tests or laboratory-developed tests (LDTs), the laboratory establishes the analytical sensitivity (lower detection limit) of each assay, as applicable." Evidence of compliance is a written procedure and records; no material is specified [7] [single-source].
• COM.40300 (accuracy, same release): "Use of matrix-appropriate reference materials, patient specimens (altered or unaltered), or other commutable materials with known concentrations or activities may be used to verify or establish accuracy" — permissive "may", with reference materials one of three listed options [7] [single-source].
• MOL.36118 "NGS Lower Limit of Detection" was revised in the 2020 edition to add "additional detail for the validation of the lower limit of detection for variants"; the change summary does not give that detail [8] [single-source].
• A CAP TODAY article (October 2017) reports the checklist "tells how to validate LLD by spiking in plasmids or nucleotides or using reference standards," that cell-line mixtures "can be used also," and quotes a checklist contributor: "You need more than all these molecular tools—you have to have a certain number of patient samples" [9] [single-source]. This is a secondary description of a pre-2020 checklist edition, not checklist text.

ISO 17034:2016 — addressed to producers, not to laboratories

• BSI's listing for BS EN ISO 17034:2016 (published 2016-11-30, status current) describes it as specifying "general requirements for the competence and consistent operation of reference material producers," superseding ISO Guide 34:2009 [11] [single-source]. Only that public description was read; clause text was not.

Professional guidelines — recommend (2017 NGS); unknown (2023 cfDNA)

• AMP/CAP 2017 (Jennings et al., JMD): "Laboratories should use reference materials composed of well-characterized normal cell lines (eg, the HapMap cell line NA12878) and allogenic or isogenic cell line mixtures to estimate performance specifications …"; NIST RM 8398 or "other commercially available reference materials" "can be used" where the reference cell line cannot document a variant class [4] [single-source]. On the text-extraction pass, the words "traceable", "certified reference material" and "ISO 17034" were not found [4].
• AMP/CAP 2023 (Lockwood et al., JMD) sets 13 consensus recommendations for ctDNA (circulating tumour DNA) assay validation and reporting [5][6]. The PubMed abstract names no material requirement [5] [paywalled]: only the abstract and AMP's 2023-10-12 press release were read.
• CLSI EP17-A2 (2nd ed., 2012-06-18): its public description covers "limits of blank, detection, and quantitation" and says nothing about materials or traceability [10] [single-source].

4. Sources

[1] 42 CFR 493.1253 Standard: Establishment and verification of performance specifications — eCFR, Office of the Federal Register (eCFR point-in-time issue 2026-08-13; accessed 2026-09-25). 42 CFR 493.1253 — https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-G/part-493/subpart-K/section-493.1253 [federal-registry] [2] 42 CFR 493.1255 Standard: Calibration and calibration verification procedures — eCFR, Office of the Federal Register (eCFR point-in-time issue 2026-08-13; accessed 2026-09-25). 42 CFR 493.1255 — https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-G/part-493/subpart-K/section-493.1255 [federal-registry] [3] 42 CFR 493.1256 Standard: Control procedures — eCFR, Office of the Federal Register (eCFR point-in-time issue 2026-08-13; accessed 2026-09-25). 42 CFR 493.1256 — https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-G/part-493/subpart-K/section-493.1256 [federal-registry] [4] Jennings LJ et al. Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the AMP and CAP — J Mol Diagn 19(3) (published 2017-03-21 online per Europe PMC, issue 2017 May; accessed 2026-09-25). PMID (PubMed identifier) 28341590; PMC6941185; DOI 10.1016/j.jmoldx.2017.01.011 — https://pmc.ncbi.nlm.nih.gov/articles/PMC6941185/ [peer-reviewed] [5] Lockwood CM et al. Recommendations for Cell-Free DNA Assay Validations: A Joint Consensus Recommendation of the AMP and CAP — J Mol Diagn (published 2023-10-06 online per Europe PMC, issue 2023 Dec; accessed 2026-09-25). PMID 37806433; DOI 10.1016/j.jmoldx.2023.09.004 — https://pubmed.ncbi.nlm.nih.gov/37806433/ [peer-reviewed] [6] Association for Molecular Pathology Publishes Best Practice Recommendations for Liquid Biopsy Assay Validations — Association for Molecular Pathology press release (published 2023-10-12; accessed 2026-09-25). [no-identifier] a society press release carries no registrar number — https://www.amp.org/AMP/assets/File/pressreleases/2023/AMP_ctDNA_Guideline_Press_Release101223.pdf [other] [7] Test Method Validation and Verification: Excerpts from CAP All Common Checklist — College of American Pathologists (published 2017, checklist release dated 2017-08-21; accessed 2026-09-25). CAP All Common Checklist, 2017 edition (release dated 2017-08-21; COM.40300, COM.40400) — https://documents-cloud.cap.org/appsuite/learning/LAP/FFoC/ValidationVerificationStudies/story_content/external_files/checklistrequirements.pdf [guideline] [8] 2020 Checklist Edition: Revised Discipline-Specific Checklist Change Summary — College of American Pathologists (published June 2020, day not given; accessed 2026-09-25). CAP checklists, 2020 edition (MOL.36118) — https://documents-cloud.cap.org/appsuite/learning/LAP/FoC_Webinars/2020ToolkitChecklistUpdate.pdf [guideline] [9] Check W. NGS checklist takes in infectious disease testing — CAP TODAY (published October 2017, day not given; accessed 2026-09-25). [no-identifier] trade magazine article with no DOI or registrar number — https://www.captodayonline.com/ngs-checklist-takes-infectious-disease-testing/ [news] [10] EP17: Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures, 2nd ed. — Clinical and Laboratory Standards Institute product page (published 2012-06-18; accessed 2026-09-25). CLSI EP17-A2, 2012 edition (second edition) — https://clsi.org/shop/standards/ep17/ [guideline] [11] BS EN ISO 17034:2016 General requirements for the competence of reference material producers — BSI Knowledge product listing (published 2016-11-30; accessed 2026-09-25). ISO 17034:2016 — https://knowledge.bsigroup.com/products/general-requirements-for-the-competence-of-reference-material-producers-1 [other]

5. Sourcing & Gaps

Well established: A laboratory must establish analytical sensitivity for an LDT (laboratory-developed test) before clinical use: CLIA 493.1253(b)(2)(iii) [1] and CAP COM.40400 [7] are separate documents from different bodies. The same pair is also silent on the material used for that establishment.

Thin: Every other line rests on one source and carries [single-source]. The MOL-specific material options rest on one secondary CAP TODAY description of a 2017-era checklist [9]. The 2023 cfDNA guideline line is [paywalled]: only the abstract was read. Jennings [4] was read as full text through a fetch tool's extraction layer, not by direct text search. Two extraction passes disagreed on the context of the "59 samples" figure, so no LoD sample-size figure from [4] is reported here.

Rescoped from class 3: REQ-0028's "why" asks whether the asset in claim 19 is something "a fast follower cannot skip". That is partly a question about competitor behaviour. It was not answered. What was researched instead is the documentary twin: what each text requires, recommends, accepts or leaves unsaid.

Out of scope: ISO 17034:2016 clause text (the iso.org OBP preview and the ANSI preview PDF both returned HTTP 403, and the full standard is sold). The current CAP MOL checklist; per [8], it downloads only for users "from a CAP-accredited laboratory". CLSI EP17-A2 full text (sold). ISO 15189 and ISO Guide 35 were not in the manifest row.

Not searched vs. not found: Not retrieved, because of a block rather than an absence: the 2023 cfDNA guideline full text (jmdjournal.org and sciencedirect.com both returned 403; there is no PMC copy), the ISO catalogue page iso.org/standard/29357, and the Springer article on ISO 17034 (DOI 10.1007/s00769-017-1285-5, which redirects to a login). A Guideline Central summary of the 2023 recommendations was fetched but not cited, because it is a secondary summary. Current MOL.36118 text was searched for and not found in any public CAP document. MOL.31015 and MOL.31025, named in the scope note, were searched for and not found publicly. Their subjects are not established here.

[inference] ISO 17034's stated scope is producer competence [11]. On that reading it would bind a reference-material vendor and not the laboratory running the LoD study. A laboratory would meet it only indirectly, by choosing an accredited producer. The clause text was not read, so this reading rests on the public description alone.

[inference] Across the texts read, third-party traceable reference material for a laboratory's own LoD is required by none. It is recommended by one professional guideline [4], and one CAP accuracy requirement accepts it as one option among several [7]. On that basis, claim 19's characterization-dataset asset looks like a convenience, not a regulatory prerequisite. The unread current MOL text could change this.

6. Claim Candidates